- Home
- ESLA vs DYAI Comparison
ESLA vs DYAI Comparison
Compare ESLA & DYAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESLA | DYAI |
|---|---|---|
| Founded | 2021 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.0M | 32.5M |
| IPO Year | 2021 | 2003 |
Fundamental Metrics
Financial Performance| Metric | ESLA | DYAI |
|---|---|---|
| Price | $0.70 | $0.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $8.00 | $3.00 |
| AVG Volume (30 Days) | 21.1K | ★ 170.0K |
| Earning Date | 05-26-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $3,090,345.00 |
| Revenue This Year | N/A | $122.79 |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.63 | $0.48 |
| 52 Week High | $3.15 | $1.60 |
Technical Indicators
Market Signals| Indicator | ESLA | DYAI |
|---|---|---|
| Relative Strength Index (RSI) | 44.63 | 23.46 |
| Support Level | $0.70 | N/A |
| Resistance Level | $0.85 | $0.88 |
| Average True Range (ATR) | 0.06 | 0.06 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 41.84 | 5.97 |
Price Performance
Historical ComparisonAbout ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.
About DYAI Dyadic International Inc.
Dyadic International Inc is a biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.